Therapeutic potential of highly diluted antibodies in antibiotic-resistant infection

Емельянова, А.Г.; Petrova, N. V.; Fremez, Christophe; Fontanié, Maxime; Тарасов, С. А.; Epstein, Oleg

doi:10.1016/j.ejps.2022.106161

Cited by 11 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…По данным доклинического исследования на модели инфекции верхних дыхательных путей, вызванной Klebsiella pneumoniae, активные компоненты препарата Рафамин® при совместном применении с амоксициллином усиливали антибактериальное действие антибиотика на устойчивый штамм Klebsiella pneumoniae на 50% [16]. Данные результаты могут иметь важное клиническое зна чение в отношении сокращения потребности в увеличе нии дозы или продолжительности приема антибактери альной терапии и, таким образом, снижать количество случаев дисбактериоза на фоне приема антибиотика.…”

Section: особенности антибактериального действия препарата рафамин®unclassified

“…Следует отметить, что при лечении ОРВИ препаратом Рафамин®, без применения антибактериальной терапии, возможно сохранение нормофлоры за счет конкурентно го подавления последней роста численности патогенных микроорганизмов. Изучение противомикробной эффек тивности компонентов, входящих в состав препарата Рафамин®, проводилось на моделях смешанной вирусно бактериальной инфекции [17], сальмонелезной инфек ции [18], а также инфекций, вызванных Klebsiella pneumoniae [16] Отмечено снижение бактериальной нагрузки и повышение выживаемости животных, а при совместном применении с антибактериальным препара том -увеличение индекса антимикробной активности в 4 -7 раз [18].…”

Section: особенности антибактериального действия препарата рафамин®unclassified

See 1 more Smart Citation

New treatment options for acute respiratory viral infections

2022

View full text Add to dashboard Cite

The treatment of acute respiratory viral infection remains an urgent public health problem. There are currently a limited number of drugs used for the treatment and prevention of this pathology with proven efficacy and safety. According to current views in the field of immunology, the most important role in immune protection against both viruses and bacteria is played by molecules and receptors that form the so-called “immune synapse”, understood as a contact of cells involved in the detection of an antigen and triggering the subsequent chain of reactions to destroy it. A complex antiviral drug that has the ability to modulate rather than block the activity of its target molecules is a product containing technologically treated antibodies to interferon gamma, CD4 and domains of the main histocompatibility complex. The combined action of its components helps to reduce the infection load on the body, reduce the severity of symptoms of SARS during the first days, reduce the duration of the infectious disease. The pharmacological effect of the drug is achieved by acting on the key molecules and receptors involved in the recognition of pathogens of both viral and bacterial origin by the immune system. In addition, the product has a direct effect on IFN-γ, which results in stopping the multiplication of viruses and protecting healthy cells from infection. The use of the antibody-based drug reduces the risk of complications and helps to increase the body’s resistance to the main pathogens of viral and bacterial infections of the respiratory tract. According to the results of clinical trials, this drug has shown high efficacy and safety in the treatment of acute respiratory viral infections (ARI) in adults. The use of antibody-based medicine in paediatric acute respiratory infections and COVID-19 treatment in an outpatient setting is currently being investigated in multicentre, double-blind, placebo-controlled randomised trials.

show abstract

Section: особенности антибактериального действия препарата рафамин®unclassified

New treatment options for acute respiratory viral infections

2022

View full text Add to dashboard Cite

show abstract

“…Компоненты препарата способствуют регуляции баланса про-/противовоспалительных цитокинов, а также синтезу противовирусных белков, которые останавливают размножение вирусов и защищают здоровые клетки от инфицирования* [4][5][6]. В экспериментальных исследованиях доказано, что при совместном применении с АБП Рафамин значительно повышал эффективность антибиотикотерапии, в том числе в отношении устойчивых штаммов возбудителей [7]. В клинических исследованиях показано, что Рафамин не только сокращал продолжительность заболевания практически на сутки, но и снижал риск осложнений, в том числе требующих применения АБП [8].…”

Section: Conference Proceedingsunclassified

Fighting against antimicrobial resistance: focus on improving the efficiency of treatment of respiratory infections in outpatient settings

2022

Consilium Medicum

View full text Add to dashboard Cite

Increasing antimicrobial resistance, including improper antibiotic use, is a global threat to public health. Reducing prophylactic antibacterial (AB) prescriptions in acute respiratory viral infection (ARVI) and reducing the incidence of bacterial complications in patients at risk of severe ARVI is an urgent medical task. For this purpose, Rafamin can be used, which has antiviral and antibacterial effects. The article provides the preliminary results of a large-scale observational study on Rafamin efficacy and safety in treating acute respiratory viral infections in routine outpatient practice. Rafamin was shown to be effective irrespective of the timing of treatment initiation with early and delayed treatment initiation. The AB prescription rate was low (0.8%) and did not increase in patients who started taking Rafamin a few days after the onset of the first disease symptoms. The data obtained are promising for treating patients at risk of severe respiratory infection. Rafamin may reduce the rate of improper AB prescribing and antibiotic resistance rate.

show abstract

“…The antibiotic resistance of a biofilm is significantly stronger than in planktonic cells and the infection becomes difficult to eradicate [ 6 , 7 ]. The number of infections caused by antibiotic-resistant is constantly increasing, and this trend is projected to continue [8] . Therefore, the demand for developing novel coatings with enhanced properties to reduce the risk of IAI is very high [9] .…”

Section: Introductionmentioning

confidence: 99%